Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials

Blood (2024) 144 (Supplement 1): 731.

https://doi.org/10.1182/blood-2024-198614

Published: 2024

Journal Articles

Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

Blood (2024) 144 (Supplement 1): 1434.

https://doi.org/10.1182/blood-2024-199110

Published: 2024

Journal Articles

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

Blood (2024) 144 (15): 1570–1580.

https://doi.org/10.1182/blood.2023023754

Published: 2024

Includes: Supplemental data

Journal Articles

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Blood (2024) 143 (23): 2363–2372.

https://doi.org/10.1182/blood.2023023502

Published: 2024

Includes: Supplemental data

Journal Articles

Genetic alterations and MRD refine risk assessment for KMT2A -rearranged B-cell precursor ALL in adults: a GRAALL study

Blood (2023) 142 (21): 1806–1817.

https://doi.org/10.1182/blood.2023021501

Published: 2023

Includes: Supplemental data

Journal Articles

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Niek G. Van Der Maas, Dimitri Breems, Clara Klerk, Thomas Pabst, Patrycja Gradowska, Bart J. Biemond, Jurgen Kuball, Janine Van Elssen, Otto Visser, Marie-Christiane Vekemans, Carlos Graux, Johan Maertens, H. Berna Beverloo, Peter J. M. Valk, Gert J. Ossenkoppele, Bob Lowenberg, Geert A. Huls, Jan J. Cornelissen, Jurjen Versluis

Blood (2023) 142 (Supplement 1): 724.

https://doi.org/10.1182/blood-2023-180812

Published: 2023

Journal Articles

NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients

Blood (2023) 142 (Supplement 1): 844.

https://doi.org/10.1182/blood-2023-179298

Published: 2023

Journal Articles

Exploring the Heterogeneity of Response to Blinatumomab in High-Risk Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: An Analysis from the QUEST Sub-Study of the Graall-2014/B Trial

Blood (2023) 142 (Supplement 1): 4349.

https://doi.org/10.1182/blood-2023-177847

Published: 2023

Journal Articles

Frontline Consolidation with Nelarabine for Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia. Results of the Graall-2014/T Atriall Phase 2 Study

Blood (2023) 142 (Supplement 1): 962.

https://doi.org/10.1182/blood-2023-177696

Published: 2023

Journal Articles

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL

Blood (2023) 141 (11): 1353–1358.

https://doi.org/10.1182/blood.2022017755

Published: 2023

Includes: Supplemental data

Journal Articles

Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma

Marlies Vanden Bempt, Koen Debackere, Sofie Demeyer, Quentin Van Thillo, Nienke Meeuws, Cristina Prieto, Sarah Provost, Nicole Mentens, Kris Jacobs, Olga Gielen, David Nittner, Seishi Ogawa, Keisuke Kataoka, Carlos Graux, Thomas Tousseyn, Jan Cools, Daan Dierickx

Blood (2022) 140 (23): 2463–2476.

https://doi.org/10.1182/blood.2022016428

Published: 2022

Includes: Supplemental data

Journal Articles

Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study

Blood (2022) 140 (Supplement 1): 507–509.

https://doi.org/10.1182/blood-2022-159397

Published: 2022

Journal Articles

In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival - Results from the Graall-2014 Trial

Blood (2022) 140 (Supplement 1): 112–114.

https://doi.org/10.1182/blood-2022-157903

Published: 2022

Journal Articles

PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL

Guillaume P. Andrieu, Milena Kohn, Mathieu Simonin, Charlotte L. Smith, Agata Cieslak, Marie-Émilie Dourthe, Guillaume Charbonnier, Carlos Graux, Françoise Huguet, Véronique Lhéritier, Hervé Dombret, Salvatore Spicuglia, Philippe Rousselot, Nicolas Boissel, Vahid Asnafi

Blood (2021) 138 (19): 1855–1869.

https://doi.org/10.1182/blood.2020010081

Published: 2021

Includes: Supplemental data

Journal Articles

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Blood (2021) 138 (Supplement 1): 512.

https://doi.org/10.1182/blood-2021-148843

Published: 2021

Journal Articles

Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2

Blood (2021) 138 (Supplement 1): 1232.

https://doi.org/10.1182/blood-2021-146163

Published: 2021

Journal Articles

IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL

Mathieu Simonin, Ludovic Lhermitte, Marie-Emilie Dourthe, Etienne Lengliné, Carlos Graux, Nathalie Grardel, Jean-Michel Cayuela, Isabelle Arnoux, Virginie Gandemer, Norbert Ifrah, Hervé Dombret, André Baruchel, Elizabeth Macintyre, Arnaud Petit, Nicolas Boissel, Vahid Asnafi

Blood (2021) 137 (12): 1690–1694.

https://doi.org/10.1182/blood.2020007959

Published: 2021

Includes: Supplemental data

Journal Articles

FER and FES tyrosine kinase fusions in follicular T-cell lymphoma

Koen Debackere, Jo-Anne van der Krogt, Thomas Tousseyn, Julio Antonio Finalet Ferreiro, Katrien Van Roosbroeck, Lukas Marcelis, Carlos Graux, Daan Dierickx, Geneviève Ameye, Peter Vandenberghe, Lucienne Michaux, Jan Cools, Iwona Wlodarska

Blood (2020) 135 (8): 584–588.

https://doi.org/10.1182/blood.2019002401

Published: 2020

Includes: Supplemental data

Journal Articles

Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial

Blood (2019) 134 (Supplement_1): 1295.

https://doi.org/10.1182/blood-2019-124029

Published: 2019

Journal Articles

Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective Study

Sophie Servais, Frédéric Baron, MD PhD, Chantal Lechanteur, Etienne Baudoux, Alexandra Briquet, Dominik Selleslag, MD, Johan A. Maertens, MD PhD, Xavier Poire, Wilfried Schroyens, MD PhD, Carlos Graux, Rik Schots, Pierre Zachée, Aurelie Ory, Julie Herman, Tessa Kerre, Yves Beguin, MD PhD

Blood (2019) 134 (Supplement_1): 37.

https://doi.org/10.1182/blood-2019-129992

Published: 2019

NARROW

Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials

Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Genetic alterations and MRD refine risk assessment for KMT2A -rearranged B-cell precursor ALL in adults: a GRAALL study

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients

Exploring the Heterogeneity of Response to Blinatumomab in High-Risk Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: An Analysis from the QUEST Sub-Study of the Graall-2014/B Trial

Frontline Consolidation with Nelarabine for Adults with High-Risk T-Cell Acute Lymphoblastic Leukemia. Results of the Graall-2014/T Atriall Phase 2 Study

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL

Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma

Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study

In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival - Results from the Graall-2014 Trial

PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2

IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL

FER and FES tyrosine kinase fusions in follicular T-cell lymphoma

Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial

Multipotent Mesenchymal Stromal Cells for Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation:a Multicenter Prospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only